Bio-Path Announces Publication in Biomedicines
April 22 2021 - 07:00AM
Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announced the publication of an analysis highlighting
the potential of prexigebersen (BP1001) within the antisense
oligonucleotide drug delivery landscape in the peer-reviewed
journal, Biomedicines.
The article, titled “The Challenges and Strategies of Antisense
Oligonucleotide Drug Delivery,” describes the challenges facing the
antisense oligonucleotide drug delivery landscape, including
stability in the bloodstream, delivery to target sites, and
cellular uptake. In addition, the authors outline why
prexigebersen, a liposome-incorporated antisense
oligodeoxynucleotide targeted against the Grb2 mRNA, has the
potential to overcome these challenges.
The article was authored by Maria Gagliardi, Ph.D., Research
Scientist at Bio-Path Holdings and Ana Tari Ashizawa, Ph.D., Senior
Vice President of Research, Development and Clinical Design at
Bio-Path Holdings.
“We believe prexigebersen has the potential to overcome the
challenges of antisense oligonucleotide drug delivery because it is
uncharged and is essentially non-toxic, as demonstrated in
preclinical and clinical studies. Additionally, its enhanced
biodistribution makes it an attractive therapeutic modality for
hematologic malignancies as well as solid tumors,” said Dr.
Ashizawa.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi nanoparticle
drugs that can be administered with a simple intravenous infusion.
Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting
the Grb2 protein), is in a Phase 2 study for blood cancers and
prexigebersen-A, a drug product modification of prexigebersen, is
under consideration by the FDA to commence Phase 1 studies in solid
tumors. This is followed by BP1002, targeting the Bcl-2 protein,
where it is being evaluated in lymphoma clinical studies. For more
information, please visit the Company's website at
http://www.biopathholdings.com.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws. These statements are based on management's current
expectations and accordingly are subject to uncertainty and changes
in circumstances. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Any statements that are
not historical facts contained in this release are forward-looking
statements that involve risks and uncertainties, including the
impact, risks and uncertainties related to COVID-19 and actions
taken by governmental authorities or others in connection
therewith, Bio-Path’s ability to raise needed additional capital on
a timely basis in order for it to continue its operations,
Bio-Path's ability to have success in the clinical development of
its technologies, the timing of enrollment and release of data in
such clinical studies and the accuracy of such data, limited
patient populations of early stage clinical studies and the
possibility that results from later stage clinical trials with much
larger patient populations may not be consistent with earlier stage
clinical trials, the maintenance of intellectual property rights,
that patents relating to existing for future patent applications
will be issued or that any issued patents will provide meaningful
protection of our drug candidates, risks relating to maintaining
Bio-Path's listing on the Nasdaq Capital Market and such other
risks which are identified in Bio-Path's most recent Annual Report
on Form 10- K, in any subsequent quarterly reports on Form 10-Q and
in other reports that Bio-Path files with the Securities and
Exchange Commission from time to time. These documents are
available on request from Bio-Path Holdings or at www.sec.gov.
Bio-Path disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact
Information: Investors
Will O’ConnorStern Investor Relations
212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path Holdings, Inc.
832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Mar 2023 to Mar 2024